Journal Mobile Options
Table of Contents
Vol. 56, No. 1, 2006
Issue release date: September 2006
Eur Neurol 2006;56:17–23

Cerebral Metabolic Alterations in McLeod Syndrome

Dydak U. · Mueller S. · Sándor P.S. · Meier D. · Boesiger P. · Jung H.H.
aInstitute for Biomedical Engineering, University and ETH Zürich, and bDepartment of Neurology, University Hospital Zürich, Zürich, Switzerland; cDepartment of Radiology, University of California, San Francisco, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

First-Page Preview
Abstract of Original Paper

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hardie RJ, Pullon HW, Harding AE, Owen JS, Pires M, Daniels GL, et al: Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991;114:13–49.
  2. Ho M, Chelly J, Carter N, Danek A, Crocker P, Monaco AP: Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994;77:869–880.
  3. Jung HH, Hergersberg M, Kneifel S, Alkadhi H, Schiess R, Weigell-Weber M, et al: McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol 2001;49:384–392.
  4. Danek A, Rubio JP, Rampoldi L, Ho M, Dobson-Stone C, Tison F, et al: McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001;50:755–764.
  5. Swash M, Schwartz MS, Carter ND, Heath R, Leak M, Rogers KL: Benign X-linked myopathy with acanthocytes (McLeod syndrome). Its relationship to X-linked muscular dystrophy. Brain 1983;106:717–733.
  6. Jung HH, Russo D, Redman C, Brandner S: Kell and XK immunohistochemistry in McLeod myopathy. Muscle Nerve 2001;24:1346–1351.
  7. Oechsner M, Buchert R, Beyer W, Danek A: Reduction of striatal glucose metabolism in McLeod choreoacanthocytosis. J Neurol Neurosurg Psychiatry 2001;70:517–520.
  8. Rinne JO, Daniel SE, Scaravilli F, Pires M, Harding AE, Marsden CD: The neuropathological features of neuroacanthocytosis. Mov Disord 1994;9:297–304.
  9. Brin MF, Hays A, Symmans WA, Marsh WL, Rowland LP: Neuropathology of McLeod phenotype is like chorea-acanthocytosis (CA). Can J Neurol Sci 1993;20(suppl):S234.

    External Resources

  10. Jung HH, Haker H: Schizophrenia as a manifestation of X-linked McLeod-neuroacanthocytosis syndrome. J Clin Psychiatry 2004;65:722–723.
  11. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  12. Jung HH, Hergersberg M, Vogt M, Pahnke J, Treyer V, Röthlisberger B, et al: McLeod phenotype associated with a XK missense mutation without hematological, neuromuscular, or cerebral involvement. Transfusion 2003;43:928–938.
  13. Duyn JH, Moonen CT: Fast proton spectroscopic imaging of human brain using multiple spin-echoes. Magn Reson Med 1993;30:409–414.
  14. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, et al: Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;12:141–152.
  15. Vanhamme L, van den BA, Van Huffel S: Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35–43.
  16. Steen RG, Hamer RM, Lieberman JA: Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005;30:1949–1962.
  17. Ernst T, Chang L, Melchor R, Mehringer CM: Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997;203:829–836.
  18. Frazier JA, Ahn MS, DeJong S, Bent EK, Breeze JL, Giuliano AJ: Magnetic resonance imaging studies in early-onset bipolar disorder: a critical review. Harv Rev Psychiatry 2005;13:125–140.
  19. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR: Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy. Neurology 1993;43:2689–2695.
  20. Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, et al: Riluzole therapy in Huntington’s disease (HD). Mov Disord 1999;14:326–330.
  21. Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, et al: 1H NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers. Neurology 1998;50:1357–1365.
  22. Hoang TQ, Bluml S, Dubowitz DJ, Moats R, Kopyov O, Jacques D, et al: Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington’s and Parkinson’s diseases. Neurology 1998;50:1033–1040.
  23. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio AA, Viano J, de Yebenes JG: Clinical correlation of striatal 1H MRS changes in Huntington’s disease. Neurology 1999;53:806–812.
  24. Heinsen H, Rub U, Bauer M, Ulmar G, Bethke B, Schuler M, et al: Nerve cell loss in the thalamic mediodorsal nucleus in Huntington’s disease. Acta Neuropathol (Berl) 1999;97:613–622.
  25. Kawakami T, Takiyama Y, Sakoe K, Ogawa T, Yoshioka T, Nishizawa M, et al: A case of McLeod syndrome with unusually severe myopathy. J Neurol Sci 1999;166:36–39.
  26. Ho MF, Chalmers RM, Davis MB, Harding AE, Monaco AP: A novel point mutation in the McLeod syndrome gene in neuroacanthocytosis. Ann Neurol 1996;39:672–675.
  27. Harms L, Meierkord H, Timm G, Pfeiffer L, Ludolph AC: Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington’s disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry 1997;62:27–30.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50